Adaptive Biotechnologies Corporation: Business Overview, Financials & Competitive Analysis
Adaptive Biotechnologies Corporation scores 7/10 on the AskCyborg Cyborg Score (Strong). Adaptive delivered 46% revenue growth and achieved profitability in its MRD business, positioning itself to drive continued growth, expand margins and achieve company-wide profitability in 2026. MRD revenue reached $212.3M in 2025 and turned profitable with Adjusted EBITDA of $12.2M, with guidance for 2026 MRD sales of $255-265M. The.
What is Adaptive Biotechnologies Corporation's industry? Adaptive Biotechnologies Corporation (adaptivebiotech.com) operates in Clinical-stage Biotechnology / Immune Medicine / Molecular Diagnostics. AskCyborg classifies Adaptive Biotechnologies Corporation under Clinical-stage Biotechnology / Immune Medicine / Molecular Diagnostics in its company registry.
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease through proprietary immune receptor sequenci...
Cyborg Score thesis
Adaptive delivered 46% revenue growth and achieved profitability in its MRD business, positioning itself to drive continued...
Read the full analyst-debate transcript →Get the Latest Adaptive Biotechnologies Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeAdaptive Biotechnologies Corporation Overview
Pro stress-test →Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease through proprietary immune receptor sequencing and analysis that decodes T-cell and B-cell receptors to identify signatures of immune response. The company reported full-year 2025 revenue of $277.0 million, a 55% increase year-over-year, with the MRD business driving growth.
Strategic Profile
Pro stress-test →Adaptive leverages proprietary immune receptor sequencing technology to decode the genetic information of T-cell and B-cell receptors. The company operates two business segments: clonoSEQ MRD (Minimal Residual Disease) diagnostics for blood cancers and immune medicine development, with a path to companywide profitability in 2026.
Competitive Landscape
Pro stress-test →The biotechnology and pharmaceutical industries are characterized by intense competition, with many companies pursuing advancements in immune medicine and larger companies with greater resources potentially overshadowing its offerings. There are concerns about incoming competition in the DLBCL space, which may affect market penetration.
Industry Context
Adaptive Biotechnologies Corporation operates in Clinical-stage Biotechnology / Immune Medicine / Molecular Diagnostics.
Key facts
Founded: 2009 · Headquarters: Seattle, US · Employees: ~620 · Revenue: $277.0M · Market cap: $1.4B